{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:46:32Z","timestamp":1786715192629,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2018]]},"DOI":"10.4103\/1673-5374.226381","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T01:56:55Z","timestamp":1519783015000},"page":"190","source":"Crossref","is-referenced-by-count":20,"title":["A new direction for Alzheimer's research"],"prefix":"10.4103","volume":"13","author":[{"given":"JamesD","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.226381-1","doi-asserted-by":"crossref","unstructured":"Aliev G, Palacios HH, Gasimov E, Obrenovich ME, Morales L, Leszek J, Bragin V, Solis Herrera A, Gokhman D (2010) Oxidative stress induced mitochondrial failure and vascular hypoperfusion as a key initiator for the development of Alzheimer disease. Pharmaceuticals (Basel) 3:158-187.","DOI":"10.3390\/ph3010158"},{"key":"key-10.4103\/1673-5374.226381-2","doi-asserted-by":"crossref","unstructured":"Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H (2009) Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 117:125-136.","DOI":"10.1007\/s00401-008-0480-1"},{"key":"key-10.4103\/1673-5374.226381-3","doi-asserted-by":"crossref","unstructured":"Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, Ames BN (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22:703-712.","DOI":"10.1096\/fj.07-9610com"},{"key":"key-10.4103\/1673-5374.226381-4","doi-asserted-by":"crossref","unstructured":"Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B (2004) How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 3:169-176.","DOI":"10.1111\/j.1474-9728.2004.00101.x"},{"key":"key-10.4103\/1673-5374.226381-5","doi-asserted-by":"crossref","unstructured":"Gella A, Durany N (2009) Oxidative stress in Alzheimer disease. Cell Adh Migr 3:88-93.","DOI":"10.4161\/cam.3.1.7402"},{"key":"key-10.4103\/1673-5374.226381-6","doi-asserted-by":"crossref","unstructured":"Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10:378-384.","DOI":"10.1111\/j.1750-3639.2000.tb00269.x"},{"key":"key-10.4103\/1673-5374.226381-7","doi-asserted-by":"crossref","unstructured":"Lonskaya I, Hebron ML, Desforges NM, Schachter JB, Moussa CE (2014) Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl) 92:373-386.","DOI":"10.1007\/s00109-013-1112-3"},{"key":"key-10.4103\/1673-5374.226381-8","doi-asserted-by":"crossref","unstructured":"No authors listed (1996) European Pentoxifylline multi-infarct dementia study. Eur Neurol 36:315-321.","DOI":"10.1159\/000117279"},{"key":"key-10.4103\/1673-5374.226381-9","doi-asserted-by":"crossref","unstructured":"Schneider LS, Sano M (2009) Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5:388-397.","DOI":"10.1016\/j.jalz.2009.07.038"},{"key":"key-10.4103\/1673-5374.226381-10","doi-asserted-by":"crossref","unstructured":"Swerdlow RH, Khan SM (2004) A \u201cmitochondrial cascade hypothesis\u201d for sporadic Alzheimer's disease. Med Hypotheses 63:8-20.","DOI":"10.1016\/j.mehy.2003.12.045"},{"key":"key-10.4103\/1673-5374.226381-11","doi-asserted-by":"crossref","unstructured":"Voziyan PA, Hudson BG (2005) Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 62:1671-1681.","DOI":"10.1007\/s00018-005-5082-7"},{"key":"key-10.4103\/1673-5374.226381-12","doi-asserted-by":"crossref","unstructured":"Weinstein JD (2017) A unique and promising combination of medications for the treatment of Alzheimer's disease. Med Hypotheses 109:53-55.","DOI":"10.1016\/j.mehy.2017.09.021"},{"key":"key-10.4103\/1673-5374.226381-13","doi-asserted-by":"crossref","unstructured":"Winblad B, Fioravanti M, Dolezal T, Logina I, Milanov IG, Popescu DC, Solomon A (2008) Therapeutic use of nicergoline. Clin Drug Investig 28:533-552.","DOI":"10.2165\/00044011-200828090-00001"},{"key":"key-10.4103\/1673-5374.226381-14","doi-asserted-by":"crossref","unstructured":"Xie SX, Ewbank DC, Chittams J, Karlawish JH, Arnold SE, Clark CM (2009) Rate of decline in Alzheimer disease measured by a dementia severity rating scale. Alzheimer Dis Assoc Disord 23:268-274.","DOI":"10.1097\/WAD.0b013e318194a324"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:26:06Z","timestamp":1786713966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.226381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["226381"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.226381","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}